Daiichi Sankyo had a day of mixed fortunes after advisers ... Quizartinib works by inhibiting FLT3 gene mutations, one of the most common genetic abnormalities in AML, associated with more ...

Prosecutors on Friday called for an 18-year prison sentence for Keisuke Yoshida, a 42-year-old former employee of pharmaceutical giant Daiichi Sankyo, who is on trial for the methanol poisoning ...

As one of the leading Japanese pharmaceutical companies with headquarters in Europe, Daiichi Sankyo aims to revolutionize treatment standards. Daiichi Sankyo, a pharmaceutical group boasting over ...

Daiichi Sankyo’s antibody-drug conjugate (ADC) platform has already delivered one drug to the market with blockbuster sales forecasts, with a second due to be filed shortly. Now, a third is ...

Daiichi Sankyo Co. will seek to maintain its edge over competitors in precision cancer therapies, by pushing ahead with clinical trials of drug candidates being developed using new technology ...

Within five years, we estimate that Daiichi Sankyo will generate over one third of total sales in the US, so major pricing reforms in this market will weigh on projected sales and margins.

Japan's Daiichi Sankyo applies for approval of mRNA COVID vaccine Approval would give Japan a home-grown mRNA vaccine of the type that has made up the bulk of its COVID inoculations so far.

Hiroyuki Okuzawa, President and COO at Daiichi Sankyo, says the company is working to boost production of its newer-generation cancer therapies that target diseased cells, across Japan ...

The campaign is presented by Daiichi-Sankyo and AstraZeneca, while Merck serves as a gold-level sponsor and Eli Lilly, Pfizer and Guardant come aboard as community sponsors. In the campaign’s ...

Daiichi Sankyo has been working on a vaccine for the Omicron strain. The drugmaker took the same path as Pfizer and Moderna in developing its current vaccine based on messenger RNA--one of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...